A comparison of the aldosterone-blocking agents eplerenone and spironolactone
about
Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectivesAldosterone receptor antagonists: effective but often forgotten.Differential efficacy profile of aldosterone receptor antagonists, depending on the type of chronic heart failure, whether with reduced or preserved left ventricular ejection fraction-results of a meta-analysis of randomized controlled trialsSensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1-deficient mice.Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension.Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study.Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension.Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation.Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?Antioxidants in kidney diseases: the impact of bardoxolone methyl.Effect of Selective Mineralocorticoid Receptor Blockade on Flow-Mediated Dilation and Insulin Resistance in Older Adults with Metabolic Syndrome.Eplerenone use in primary aldosteronism during pregnancy.Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trialEstimation of the Mechanism of Adrenal Action of Endocrine-Disrupting Compounds Using a Computational Model of Adrenal Steroidogenesis in NCI-H295R Cells.Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats.Endocrine and hypertensive disorders of potassium regulation: primary aldosteronismADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference.Which antihypertensive drugs are the most nephroprotective and why?Angiotensin inhibition and longevity: a question of hydration.Drug therapy for resistant hypertension: simplifying the approach.Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes.Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.Emerging drugs which target the renin-angiotensin-aldosterone system.Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure.Mineralocorticoid receptor antagonists: their use and differentiation in Japan.Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms.Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention.Mineralocorticoid receptor antagonists attenuate exaggerated exercise pressor reflex responses in hypertensive rats.Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: a systematic review and meta-analysis.Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions.Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer.Eplerenone for hypertension.Effects of aldosterone and related steroids on LPS-induced increased expression of inducible NOS in rat aortic smooth muscle cells.Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis.The Impact Exerted on Clinical Outcomes of Patients With Chronic Heart Failure by Aldosterone Receptor Antagonists: A Meta-Analysis of Randomized Controlled Trials.Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease.Effect of eplerenone, a selective aldosterone blocker, on the development of diabetic nephropathy in type 2 diabetic rats.Pulsatile Cortisol Feedback on ACTH Secretion Is Mediated by the Glucocorticoid Receptor and Modulated by GenderAldosterone receptor inhibition alters the viscoelastic biomechanical behavior of the aortic wall.
P2860
Q26741152-2273E2F0-B7CA-4883-B37A-9E5A00A3288CQ33688485-0642A7C5-B283-4320-A120-8CE87C40C391Q33714645-2A142B95-9BDA-4AB9-959B-1017F8AE7FA0Q33917152-FAF21C9C-107F-41B8-8A3B-91B59BB68819Q34013918-82168DAA-CC2C-46C5-B309-208D10317803Q34071671-52833A78-B51E-493D-B0E6-6B963ECA4BC1Q34600299-5FCC5401-5B19-4D5A-8862-6D3A9A26175EQ35031677-1C4CDAF1-0D4D-457E-B4B3-429D896B2260Q35272248-B63E21B1-F1D5-480E-A246-EA1B4A2A1A8FQ36026304-E36679F2-9248-403D-98A6-61DAB98A9233Q36162444-23A4CDBE-A914-4C96-88FA-10DB849158CBQ36445422-1734003C-964E-46BE-9A11-A90280A79DF7Q36448508-E38E657E-8309-44DD-9998-142C98187939Q36637579-59D38FD2-B283-4AF3-85DF-208E5BB893C3Q36887421-B8F47083-CEC3-45F8-A313-3EB4D2E5BF3BQ37107686-CF8C55BE-5F78-48EF-940E-A7F143621C45Q37759964-24F1CB89-1D60-419E-8709-48174BD17F18Q37803235-57F60580-8306-4076-8AE2-C75B25016233Q37821796-22F9C428-1895-40AE-BBE2-16B37273DA82Q37832774-CBEEF4CE-981C-496C-9B71-C4B96BE0C86FQ37889518-5799BA7C-D48B-457C-A6C5-53948FB3E3CCQ37897992-9F594A67-F910-4C8C-B795-08BE3B790E92Q37929786-E51DDCB2-A837-409D-AF32-3D21AF3FAF23Q38040730-058596F5-D052-44AE-A736-A17E69F72874Q38061551-556C59BB-D8DB-49D3-BCE9-85BF25A10078Q38123754-39477755-FB37-479D-AECB-B0B1D224CBC5Q38182029-880D3CE0-AB12-4DA3-9C2C-2D9ADEF1BC1EQ38385760-6E0F55B0-B1B1-4EDF-AF5B-90FAA453D4D0Q38667235-DB36AF44-68E9-44B4-BFA9-C66A402BD241Q38746216-71F50F66-F914-44FB-B90B-1E8CCBF9E54EQ38817943-D77C26B5-B2BA-4D06-BB5B-7998D6DDE5EDQ38834858-DF79B482-8DB1-469C-B828-CBC74B1BF899Q38937259-96DA04A3-52CC-4A40-806B-648B282F8DC8Q40006665-DAED7BB7-23A5-41F4-B895-D7612C6C4EE0Q40170291-B1CBAD6E-2605-4FCF-835D-E2CC2189B5C8Q40799105-376185BA-1FA8-40F6-AA53-A853B3564914Q41773994-794F6C46-6A23-4804-A687-206840CC7445Q41970822-3C2C2E22-8C1F-45BF-B83A-9BC02CEDE2ADQ42733118-95F82E3C-B91A-4991-A42C-8A25A0DB2CB0Q43093139-E0D6E47B-0CC6-4146-97D7-0B05CE62A86E
P2860
A comparison of the aldosterone-blocking agents eplerenone and spironolactone
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
A comparison of the aldosterone-blocking agents eplerenone and spironolactone
@ast
A comparison of the aldosterone-blocking agents eplerenone and spironolactone
@en
A comparison of the aldosterone-blocking agents eplerenone and spironolactone
@nl
type
label
A comparison of the aldosterone-blocking agents eplerenone and spironolactone
@ast
A comparison of the aldosterone-blocking agents eplerenone and spironolactone
@en
A comparison of the aldosterone-blocking agents eplerenone and spironolactone
@nl
prefLabel
A comparison of the aldosterone-blocking agents eplerenone and spironolactone
@ast
A comparison of the aldosterone-blocking agents eplerenone and spironolactone
@en
A comparison of the aldosterone-blocking agents eplerenone and spironolactone
@nl
P3181
P356
P1433
P1476
A comparison of the aldosterone-blocking agents eplerenone and spironolactone
@en
P2093
Gordon H Williams
Henry Krum
P2860
P304
P3181
P356
10.1002/CLC.20324
P407
P577
2008-04-01T00:00:00Z